Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (4): 117-121     DOI: 10.31083/j.rcm.2018.04.3188
Review Previous articles | Next articles
Pulmonary hypertension: a neglected risk condition in renal patients?
Davide Bolignano1, *(), Anna Pisano1, Graziella D’Arrigo1
1 CNR-Institute of Clinical Physiology, 89124 Reggio Calabria, Italy
Download:  PDF(640KB)  ( 790 )
Export:  BibTeX | EndNote (RIS)      
Pulmonary hypertension (PH), an acknowledged risk condition at the community level and in patients with heart or lung diseases, is now getting growing attention as a new, potentially modifiable cardiovascular (CV) risk factor also in individuals affected by kidney diseases. PH is highly prevalent in this setting, being about 3 to 6 times more frequent that in the general population and portends a risk excess for mortality, adverse CV outcomes and also worsen graft function in kidney transplant recipients. Several factors might be involved to explain PH in renal patients, including but not limited to volume overload, breath disorders, left heart dysfunction and the presence of highflow artero-venous fistulas. Targeting PH might lead to improved outcomes in renal patients but the lack of specific interventional studies and the need for more accurate evidence adopting standardized ways to assess PH leave the issue open for future research.
Key words:  Pulmonary hypertension      chronic kidney disease      end-stage kidney disease      mortality      cardiovascular disease     
Published:  30 December 2018     
*Corresponding Author(s):  Davide Bolignano, E-mail:   

Cite this article: 

Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.

URL:     OR

[1] Abassi z, Nakhoul f, Khankin e, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens. 2006;15:353-360.
[2] Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant. 2012;27: 3908-3914.
[3] Arrigoni FI, Vallance P, Haworth SG. et al. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation. 2003;107:1195-1201.
[4] Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55-S66.
[5] BarcelóA, de la Pe?a M, AYLLON O, et al. Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration. 2009;77:85-90.
[6] Bolignano D, Lennartz S, Leonardis D, et al. High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease. Kidney Int. 2015;88:130-136.
[7] Bolignano D, Pisano A, Coppolino G, et al. Pulmonary Hypertension Predicts Adverse Outcomes in Renal Patients: A Systematic Review and Meta-Analysis. Ther Apher Dial. 2018 Nov 22.
[8] Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61:612-622.
[9] Buemi M, Senatore M, Gallo GC, et al. Pulmonary hypertension and erythropoietin. Kidney Blood Press Res. 2007;30:248-252.
[10] Eggers PW. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens. 2011;20:241-245.
[11] Fabbian F, Cantelli S, Molino C, et al. Pulmonary hypertension in dialysis patients: a cross-sectional italian study. Int J Nephrol. 2010;30
. [12] Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34:1219-1263.
[13] George MG, Schieb LJ, Ayala C, et al. Pulmonary hypertension surveillance: United States, 2001 to 2010. Chest. 2014;146:476-495.
[14] Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest. 1998;114:208S-212S.
[15] Havlucu Y, Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration. 2007;74:503-510.
[16] Honeycutt AA, Segel JE, Zhuo X, et al. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24:1478-1483.
[17] Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ. 2005;54:1-28.
[18] Issa N, Krowka MJ, Griffin MD, et al. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008;86:1384-1388.
[19] Kiykim AA, Horoz M, Ozcan T, et al. Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: the effect of dialyzer composition. Ren Fail. 2010;32:1148-1152.
[20] Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146-1150.
[21] Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119:2663-2670.
[22] Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12:143-155.
[23] Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant. 2005;20:1686-1692.
[24] Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003;42:303-309.
[25] Pabst S, Hammerstingl C, Hundt F, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One. 2012;7:1-7.
[26] Ramasubbu K, Deswal A, Herdejurgen C, et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med. 2010;3:279-286.
[27] Ryan JJ, Thenappan T, Luo N, et al. The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ. 2012;2:107-121.
[28] Sakaguchi Y, Shoji T, Kawabata H, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a crosssectional study. Clin J Am Soc Nephrol. 2011;6:995-1000.
[29] Sasaki A, Doi S, Mizutani S, et al. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1480-L1487.
[30] Sica AL, Greenberg HE, Ruggiero DA. et al. Chronic-intermittent hypoxia: a model of sympathetic activation in the rat. Respir Physiol. 2000;121:173-184.
[31] Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43-S54.
[32] Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98:1805-1811.
[33] Ward JP, Mcmurtry IF. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol. 2009;9:287-296.
[34] Yigla M, Fruchter O, Aharonson D, et al. Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int. 2009;75:969-975.
[35] Yigla M, Keidar Z, Safadi I, et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int. 2004;66:806-810.
[36] Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123:1577-1582.
[37] Zlotnick, DM, Axelrod DA, Chobanian MC, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010;25:3090-3096.
[38] Zoccali C. The endothelium as a target in renal diseases. J Nephrol. 2007;20:S39-S44.
[39] Zoccali C, Bode-boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117.
[1] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[2] Malik Bisserier, Natasha Pradhan, Lahouaria Hadri. Current and emerging therapeutic approaches to pulmonary hypertension[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 163-179.
[3] Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
[4] Peter A. McCullough, John Eidt, Janani Rangaswami, Edgar Lerma, James Tumlin, Kevin Wheelan, Nevin Katz, Norman E. Lepor, Kris Vijay, Sandeep Soman, Bhupinder Singh, Sean P. McCullough, Haley B. McCullough, Alberto Palazzuoli, Gaetano M. Ruocco, Claudio Ronco. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 1-7.
[5] Megan S. Joseph, Maryse Palardy, Nicole M. Bhave. Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 31-39.
[6] Akanksha Agrawal, Hafeez Ul Hassan Virk, Iqra Riaz, Deepanshu Jain, Byomesh Tripathi, Chayakrit Krittanawong, Benham Bozorgnia, Vincent Figueredo, Peter A. McCullough, Janani Rangaswami. Predictors of 30-day re-admissions in patients with infective endocarditis: a national population based cohort study[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 123-127.
[7] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[8] Faeq Husain-Syed, Horst-Walter Birk, Khodr Tello, Manuel J. Richter, Claudio Ronco, Peter A. McCullough, Tanja Schörmann, Fiorenza Ferrari, Gökhan Yücel, Babak Yazdani, Hans-Dieter Walmrath, Werner Seeger, Henning Gall, H. Ardeschir Ghofrani. Alterations in Doppler-derived renal venous stasis index during decompensation of right heart failure and fluid overload in a patient with pulmonary hypertension[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 263-266.
[9] Shanna J. Hardin, Mahavir Singh, Wintana Eyob, Jack C. Molnar, Rubens P. Homme, Akash K. George, Suresh C. Tyagi. Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 121-128.
[10] Wenyan Jiang, Mei Wang. New insights into the immunomodulatory role of exosomes in cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 153-160.
[11] Wan Chin Hsieh, Anas Aboud, Brandon M. chael Henry, Mohamed Omara, Jaroslav Lindner, Jan Pirk. Serum albumin in patients undergoing transcatheter aortic valve replacement: A meta-analysis[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 161-169.
[12] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[13] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[14] Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.
[15] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
No Suggested Reading articles found!